在CDR-SB©上临床进展:在主要遗传性和零星性阿尔茨海默病群体中,每0.5个单位的无进展时间
Guoqiao Wang1,2, Yan Li1, Eric McDade1
1Department of Neurology, Washington University, School of Medicine, St. Louis, Missouri, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|September 5, 2025
概括
无进展时间 (PFT) 提供了一种衡量阿尔茨海默病 (AD) 治疗效果的新方法. 这种方法估计患者在特定阶段停留的时间,有助于临床试验的解释.
科学领域:
- 神经科学
- 临床神经学
- 生物统计学
背景情况:
- 临床痴呆症评分总和 (CDR-SB) 是阿尔茨海默病 (AD) 临床试验的标准指标.
- CDR-SB得分的小差异可能导致解释治疗效果的困难.
- 需要新的指标来更好地评估阿尔茨海默病的治疗干预措施.
研究的目的:
- 在CDR-SB尺度的每0.5个单位增量时估计无进展时间 (PFT).
- 评估PFT作为评估AD治疗效果的潜在替代措施.
- 在主导性遗传性AD (DIAD) 和零星AD群体中比较PFT.
主要方法:
- 在不同CDR-SB分数级别的参与者中计算PFT.
- 分析了阿尔茨海默病神经成像计划 (ADNI) 队列的数据.
- 模拟了假设的3年莱卡内马布治疗对偶发性AD的PFT的影响.
主要成果:
- 随着CDR- SB水平的变化,PFT显著变化,在较低的分数下更长 (≤2. 0),在较高的分数下更短 (≥5. 0).
- 与ADNI队列相比,DIAD队列表现出类似的PFT趋势,但持续时间较短.
- 据估计,在偶发性AD患者中,使用lecanemab治疗3年可以延迟疾病进展0. 62年.
结论:
- 无进展时间 (PFT) 可以作为AD临床进展和治疗效果的有价值的基准.
- 在缺乏安慰剂对照的开放扩展或单臂试验中,PFT对于评估治疗特别有用.
- 在阿尔茨海默病研究中进一步验证PFT可能会提高治疗效益的解释.
更多相关视频
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.3K
06:49A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
Published on: October 6, 2015
19.9K
相关概念视频
01:26Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
02:07Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K